Study Stopped
Lack of available clinical time to complete
Saccadometry in Primary Headache Syndromes
1 other identifier
observational
42
1 country
2
Brief Summary
Migraine is one of the commonest neurological disorders, affecting up to 12% of the general population, but remains relatively under-diagnosed and under-treated. Migraine has a wide socioeconomic impact and brings a large economic burden; estimates suggest that disability due to migraine costs \> €27 billion per annum across Europe. Despite its prevalence and impact, migraine pathophysiology is poorly understood. A wider understanding of the functional changes in this disorder would be beneficial to both diagnosis and treatment. Saccades are the rapid eye movements we make when moving the eyes to a new object in our visual field. Reaction time studies have been used to investigate Huntington's disease and Parkinson's disease with great success. These use saccadic tasks (monitoring eye movements). Even at rest we make approximately three saccades per second, so a lot of data can quickly be gathered with non-invasive testing. We hope to understand more of the underlying mechanisms of migraine by studying reaction time in migraine patients. Our previous pilot study, with less stringent inclusion and exclusion criteria, looked at fewer patients (32 migraineurs and 32 controls), and found that migraineurs showed significantly different saccadic patterns to non-migraineurs. This study firstly seeks to corroborate the saccadometric findings of our earlier pilot study in a group of migraineurs, and secondly to explore the specificity of these findings in migraine by also studying patients with another primary headache syndrome, namely cluster headache. Migraine is known to be a dynamic disorder, with previous studies showing longitudinal changes in the migraine brain. To explore this further we hope to record longitudinally (Every day for 21 days) in a small subset of migraineurs to identify potential longitudinal changes in saccadic reaction time. Because of the portability of the equipment this could be done in the subjects own home if they preferred.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2011
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 14, 2011
CompletedFirst Posted
Study publicly available on registry
July 15, 2011
CompletedStudy Start
First participant enrolled
August 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 27, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 27, 2017
CompletedOctober 31, 2017
October 1, 2017
6.2 years
July 14, 2011
October 27, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
To see if Saccadometry results differ between controls and migraine subjects
By May 2019
Study Arms (4)
Episodic Migraine.
menstrual migraine
Cluster Headache patients
control (non-headache group)
Eligibility Criteria
From hospital Headache clinics (secondary and tertiary)
You may qualify if:
- Male or female and aged between 18 and 60 years in good general health apart from suffering from headaches (test group).
- Migraine and cluster headache will be diagnosed according to ICHD-II diagnostic criteria (6).
- Migraineurs must suffer at least two migraine attacks per year and no more than 5 attacks per month.
You may not qualify if:
- Any other neurological disorder such as stroke, multiple sclerosis, epilepsy, concussion within the past year, psychiatric disorders, visual disorders.
- Use of migraine prophylactic medication in the last month or acute migraine therapy in the 3 days prior to testing.
- Patients on any medication to treat depression in their case
- Headache during testing or within 3 days before and after testing.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tim Younglead
Study Sites (2)
Neurology Department, Whittington Hospital
London, N19 5NF, United Kingdom
The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, and The John Radcliffe hospital, Oxford, The Whittington Hospital N19 5NF London
London, WC1N 3BG, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
July 14, 2011
First Posted
July 15, 2011
Study Start
August 1, 2011
Primary Completion
October 27, 2017
Study Completion
October 27, 2017
Last Updated
October 31, 2017
Record last verified: 2017-10